JAK inhibitors redefining atopic dermatitis treatment
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan).
JAK inhibitors represent a breakthrough in addressing inflammatory conditions like atopic dermatitis (AD), providing a targeted approach that enhances treatment efficacy and safety, while promising new therapeutic options for diverse patient populations, says pharma analytics company GlobalData.
Incyte’s (Nasdaq: INCY) Opzelura (ruxolitinib) is a topical JAK 1/2 inhibitor that has been approved for AD in the USA. Its role in AD treatment has been explored, with completed clinical trials for Opzelura in AD involving diverse AD patient populations; the Phase III TRuE AD1 (NCT03745638) and TRuE AD2 (NCT03745651) studies were aimed at adolescents and adults, and the TRuE AD3 (NCT04921969) study was aimed at children.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze